CLDF Title
Home | Contact Us | Bookmark
HBV HE HCC HCV
About CLDF Centers of Educational Expertise  
CME Dinner Meetings Telewebs Webcasts Slide Library Abstract Library Conference Highlights
 
Back  
 
Reuters Health Information (2004-10-28): Early immune response plays key role in hepatitis C clearance

Clinical

Early immune response plays key role in hepatitis C clearance

Last Updated: 2004-10-28 9:55:12 -0400 (Reuters Health)

NEW YORK (Reuters Health) - A negative hepatitis C virus (HCV) RNA test and a broad cell-mediated immune response during the first month of infection are good predictors of viral clearance, according to a report in the November issue of Gut.

"Understanding the virus host interactions, which enable a proportion of patients with acute infection to clear HCV, is probably a key to the development of more effective treatment and prevention strategies," the authors explain.

Dr. E. Spada from National Center of Epidemiology, Rome, and colleagues in the Acute Hepatitis C Italian Study Group followed the clinical course of 34 consecutive patients with acute hepatitis C.

Nine of 10 patients with a self-limiting infection had a negative HCV RNA test within the first month of symptom onset, the authors report, compared with 4 of 24 patients who developed chronic HCV infection (p < 0.01).

A greater proportion of women (5/7) than men (5/27) experienced a self-limiting course, the report indicates, and patients who achieved a normal ALT level early and a higher median peak bilirubin level were more likely to have a self-limiting course of the disease. After adjusting for "age, sex, ALT and bilirubin levels at the onset, the only independent factor associated to a self self-limiting course of acute hepatitis C was female sex," the investigators report.

Strong T cell responses to multiple HCV antigens during the early phase of acute HCV infection was also associated with resolution of the infection, the researchers note (p < 0.01).

HLA class II type was not significantly associated with HCV outcomes, the results indicate, but HLA-DRB1*1101 was more frequent in resolving patients and was the allele detected in two women with the strongest and broadest T cell response.

"These findings suggest that repeated evaluation of HCV RNA status until the third month from the onset of disease can serve as a good predictor of the outcome of the infection and can be used as a useful criterion to decide the beginning of antiviral treatment," the investigators write.

"By implementing a T cell assay together with RNA detection tests within the first month from the onset of symptoms," the authors conclude, "one could select with high diagnostic sensitivity a group of patients with high probability to resolve the infection, preventing them having to undergo an early antiviral treatment."

"If such a combined test failed in predicting a favorable course," the researchers add, "treatment could still achieve high frequency of sustained virological response if started within the first 6 months from disease onset."

Gut 2004;53:1673-1681.

 
 
 
 
                 
 
HBV
Webcasts
Slide Library
Abstract Library
 
HE
CME Dinner Meeting
Webcasts
Slide Library
Abstract Library
 
HCC
Slide Library
Abstract Library
 
 
HCV
Webcasts
Slide Library
Abstract Library
 
CLDF Follow Us
   
 
About CLDF
Mission Statement
Board of Trustees
Board of Advisors
CLDF Supporters
 
Other Resources
Liver News Library
Journal Abstracts
Hep C Link to Care
 
Centers of
Educational Expertise
Regional Map
     
   
  The Chronic Liver Disease Foundation is a non-profit organization with content developed specifically for healthcare professionals.
© Copyright 2012-2014 Chronic Liver Disease Foundation. All rights reserved. This site is maintained as an educational resource for US healthcare providers only.
Use of this Web site is governed by the Chronic Liver Disease Foundation terms of use and privacy statement.